Therapeutic effect of Terminalia Chebula extract on Parkinson's disease

The effect of a capsule prepared from the aqueous extract of Terminalia Chebula on catatonia in patients with Parkinson's disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201029049187N1

Enrollment

Registered

2020-12-30

Start date

2012-10-21

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease. Parkinson's disease

Interventions

Intervention 1: Intervention group: Terminalia Chebula extract capsule group: In addition to the main treatment for Parkinson's disease, which is L-dopa judgment, patients were given capsules containi

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients over 30 years of age with Parkinson'sAge under 70 years Patients who have been definitively diagnosed by a Parkinson's neurologist Patients who have had symptoms for less than 3 months

Exclusion criteria

Exclusion criteria: Age over 70 years Age under 30 years Uncertain diagnosis of Parkinson's Has had Parkinson's symptoms for more than 3 months and has not been diagnosed

Design outcomes

Primary

Measure	Time frame
Parkinson's catatonia. Timepoint: Before the intervention and week 2, 4, 6 after intervention. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Quality of life Score and Symptoms. Timepoint: Before the start of the study and 2 months after the start of the study. Method of measurement: Parkinson's Disease Questionnaire =PDQ-39.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Vahid Dastjerdi

Islamic Azad University

Mvdastjerdi@yahoo.com+98 21 3334 8036

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026